Visualitzant VHIO - Articles científics per títol
Ara mostrant els elements 538-557 d 865
-
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
(Oxford University Press, 2023-01) -
Oncological care organisation during COVID-19 outbreak
(BMJ, 2020-08-26) -
Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers
(Nature Research, 2021-08-16) -
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
(American Society of Clinical Oncology, 2021-03-20) -
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
(Frontiers Media, 2023-02-24) -
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
(American Society of Clinical Oncology, 2022-09-01) -
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
(American Society of Clinical Oncology, 2023-01-20) -
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer
(Oxford University Press, 2023-04) -
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
(SAGE Publications, 2019-05-10) -
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
(American Association for Cancer Research, 2023-01-04)